Literature DB >> 21690334

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.

Anja Seubert1, Samuele Calabro, Laura Santini, Barbara Galli, Alessia Genovese, Sara Valentini, Susanna Aprea, Annalisa Colaprico, Ugo D'Oro, Marzia M Giuliani, Michele Pallaoro, Mariagrazia Pizza, Derek T O'Hagan, Andreas Wack, Rino Rappuoli, Ennio De Gregorio.   

Abstract

Oil-in-water emulsions have been successfully used to increase the efficacy, immunogenicity, and cross-protection of human vaccines; however, their mechanism of action is still largely unknown. Nlrp3 inflammasome has been previously associated to the activity of alum, another adjuvant broadly used in human vaccines, and MyD88 adaptor protein is required for the adjuvanticity of most Toll-like receptor agonists. We compared the contribution of Nlrp3 and MyD88 to the adjuvanticity of alum, the oil-in-water emulsion MF59, and complete Freund's adjuvant in mice using a three-component vaccine against serogroup B Neisseria meningitidis (rMenB). Although the basal antibody responses to the nonadjuvanted rMenB vaccine were largely dependent on Nlrp3, the high-level antibody responses induced by alum, MF59, or complete Freund's adjuvant did not require Nlrp3. Surprisingly, we found that MF59 requires MyD88 to enhance bactericidal antibody responses to the rMenB vaccine. Because MF59 did not activate any of the Toll-like receptors in vitro, we propose that MF59 requires MyD88 for a Toll-like receptor-independent signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690334      PMCID: PMC3131326          DOI: 10.1073/pnas.1107941108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.

Authors:  Ali H Ellebedy; Christopher Lupfer; Hazem E Ghoneim; Jennifer DeBeauchamp; Thirumala-Devi Kanneganti; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

2.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

3.  Immunology: Toll-like receptors and antibody responses.

Authors:  D Nemazee; A Gavin; K Hoebe; B Beutler
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

4.  Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.

Authors:  John Donnelly; Duccio Medini; Giuseppe Boccadifuoco; Alessia Biolchi; Joel Ward; Carl Frasch; E Richard Moxon; Maria Stella; Maurizio Comanducci; Stefania Bambini; Alessandro Muzzi; William Andrews; Jie Chen; George Santos; Laura Santini; Philip Boucher; Davide Serruto; Mariagrazia Pizza; Rino Rappuoli; Marzia Monica Giuliani
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-20       Impact factor: 11.205

5.  Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

Authors:  Hanfen Li; Stephen B Willingham; Jenny P-Y Ting; Fabio Re
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type.

Authors:  Anne-Cécile Rimaniol; Gabriel Gras; François Verdier; Francis Capel; Vladimir B Grigoriev; Fabrice Porcheray; Elisabeth Sauzeat; Jean-Guy Fournier; Pascal Clayette; Claire-Anne Siegrist; Dominique Dormont
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

7.  The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism.

Authors:  M Ulanova; A Tarkowski; M Hahn-Zoric; L A Hanson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

8.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Authors:  O Adachi; T Kawai; K Takeda; M Matsumoto; H Tsutsui; M Sakagami; K Nakanishi; S Akira
Journal:  Immunity       Date:  1998-07       Impact factor: 31.745

9.  The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells.

Authors:  Anja Seubert; Elisabetta Monaci; Mariagrazia Pizza; Derek T O'Hagan; Andreas Wack
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  68 in total

1.  Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Authors:  Geetanjali Agnihotri; Breanna M Crall; Tyler C Lewis; Timothy P Day; Rajalakshmi Balakrishna; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

Review 2.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

3.  Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.

Authors:  Ryan F Russell; Jacqueline U McDonald; Laura Lambert; John S Tregoning
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

4.  How squalene GLAdly helps generate antigen-specific T cells via antigen-carrying neutrophils and IL-18.

Authors:  Justin D Kedl; Ross M Kedl
Journal:  Eur J Immunol       Date:  2015-02       Impact factor: 5.532

5.  Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.

Authors:  Eun-Ju Ko; Youri Lee; Young-Tae Lee; Yu-Jin Jung; Vu L Ngo; Min-Chul Kim; Ki-Hye Kim; Bao-Zhong Wang; Andrew T Gewirtz; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-05-14       Impact factor: 3.641

Review 6.  Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.

Authors:  Thomas W Dubensky; David B Kanne; Meredith L Leong
Journal:  Ther Adv Vaccines       Date:  2013-11

Review 7.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

Review 8.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

9.  Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Amanda L Blasius; Ivo Rimann; Keiko Ozato; Dwight H Kono; Bruce Beutler; Argyrios N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

10.  An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.

Authors:  James P Phipps; Karen M Haas
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.